Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice

Hepatology

Volumn 63, Issue 6, 2016, Pages 1828-1841

  Hamilton, James P ^a   Koganti, Lahari ^a   Muchenditsi, Abigael ^a   Pendyala, Venkata S ^a   Huso, David ^a   Hankin, Joseph ^b   Murphy, Robert C ^b   Huster, Dominik ^c   Merle, Uta ^d   Mangels, Christopher ^a   Yang, Nan ^a   Potter, James J ^a   Mezey, Esteban ^a   Lutsenko, Svetlana ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Deakoness Hospital   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4BETA HYDROXYCHOLESTEROL; 5,6BETA EPOXYCHOLESTEROL; 7ALPHA,BETA HYDROXYCHOLESTEROL; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COPPER; HETERODIMER; INTERLEUKIN 1BETA; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; OXYSTEROL; RETINOID X RECEPTOR BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENETIC MARKER; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIPID METABOLISM; LIVER FIBROSIS; LIVER FUNCTION; LIVER HISTOLOGY; LIVER METABOLISM; LIVER PROTECTION; METAL BINDING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WILSON DISEASE;

EID: 84978193472     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28406     Document Type: Article

References (39)

1. Gross JB, Jr., Myers BM, Kost LJ, Kuntz SM, LaRusso NF. Biliary copper excretion by hepatocyte lysosomes in the rat. Major excretory pathway in experimental copper overload. J Clin Invest 1989;83:30-39.
2. Roberts EA, Schilsky ML, American Association for Study of Liver D. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089-2111.
3. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 2007;56:115-120.
4. Schilsky ML, Roberts EA, Hahn S, Askari F. Costly choices for treating Wilson's disease. Hepatology 2015;61:1106-1108.
5. −/− (Wilson disease gene) knockout mice. Am J Pathol 2006;168:423-434.
6. Kegley KM, Sellers MA, Ferber MJ, Johnson MW, Joelson DW, Shrestha R. Fulminant Wilson's disease requiring liver transplantation in one monozygotic twin despite identical genetic mutation. Am J Transplant 2010;10:1325-1329.
7. Levy E, Brunet S, Alvarez F, Seidman E, Bouchard G, Escobar E, et al. Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease. Life Sci 2007;80:1472-1483.
8. Seessle J, Gohdes A, Gotthardt DN, Pfeiffenberger J, Eckert N, Stremmel W, et al. Alterations of lipid metabolism in Wilson disease. Lipids Health Dis 2011;10:83.
9. Huster D, Purnat TD, Burkhead JL, Ralle M, Fiehn O, Stuckert F, et al. High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. J Biol Chem 2007;282:8343-8355.
10. Buiakova OI, Xu J, Lutsenko S, Zeitlin S, Das K, Das S, et al. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet 1999;8:1665-1671.
11. Hamilton JP, Potter JJ, Koganti L, Meltzer SJ, Mezey E. Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma. Hepatol Res 2014;44:1357-1366.
12. Potter JJ, Rennie-Tankesley L, Mezey E. Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration. J Hepatol 2003;38:281-288.
13. McDonald JG, Smith DD, Stiles AR, Russell DW. A comprehensive method for extraction and quantitative analysis of sterols and secosteroids from human plasma. J Lipid Res 2012;53:1399-1409.
14. Chen S, Wang K, Wan YJ. Retinoids activate RXR/CAR-mediated pathway and induce CYP3A. Biochem Pharmacol 2010;79:270-276.
15. Singh AB, Guleria RS, Nizamutdinova IT, Baker KM, Pan J. High glucose-induced repression of RAR/RXR in cardiomyocytes is mediated through oxidative stress/JNK signaling. J Cell Physiol 2012;227:2632-2644.
16. Hoshikawa Y, Kanki K, Ashla AA, Arakaki Y, Azumi J, Yasui T, et al. c-Jun N-terminal kinase activation by oxidative stress suppresses retinoid signaling through proteasomal degradation of retinoic acid receptor alpha protein in hepatic cells. Cancer Sci 2011;102:934-941.
17. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-614.
18. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831-2838.
19. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med 2003;9:213-219.
20. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
21. Zimmerman TL, Thevananther S, Ghose R, Burns AR, Karpen SJ. Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. J Biol Chem 2006;281:15434-15440.
22. Chang KC, Shen Q, Oh IG, Jelinsky SA, Jenkins SF, Wang W, et al. Liver X receptor is a therapeutic target for photoaging and chronological skin aging. Mol Endocrinol 2008;22:2407-2419.
23. Torra IP, Ismaili N, Feig JE, Xu CF, Cavasotto C, Pancratov R, et al. Phosphorylation of liver X receptor alpha selectively regulates target gene expression in macrophages. Mol Cell Biol 2008;28:2626-2636.
24. Wu C, Hussein MA, Shrestha E, Leone S, Aiyegbo MS, Lambert WM, et al. Modulation of macrophage gene expression via liver X receptor alpha serine 198 phosphorylation. Mol Cell Biol 2015;35:2024-2034.
25. Braiterman LT, Gupta A, Chaerkady R, Cole RN, Hubbard AL. Communication between the N and C termini is required for copper-stimulated Ser/Thr phosphorylation of Cu(I)-ATPase (ATP7B). J Biol Chem 2015;290:8803-8819.
26. Veldhuis NA, Valova VA, Gaeth AP, Palstra N, Hannan KM, Michell BJ, et al. Phosphorylation regulates copper-responsive trafficking of the Menkes copper transporting P-type ATPase. Int J Biochem Cell Biol 2009;41:2403-2412.
27. Acevedo KM, Opazo CM, Norrish D, Challis LM, Li QX, White AR, et al. Phosphorylation of amyloid precursor protein at threonine 668 is essential for its copper-responsive trafficking in SH-SY5Y neuroblastoma cells. J Biol Chem 2014;289:11007-11019.
28. Beaven SW, Wroblewski K, Wang J, Hong C, Bensinger S, Tsukamoto H, et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 2011;140:1052-1062.
29. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, et al. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
30. Garcia-Ruiz C, Colell A, Mari M, Morales A, Calvo M, Enrich C, et al. Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest 2003;111:197-208.
31. Goyal MK, Sinha S, Patil SA, Jayalekshmy V, Taly AB. Do cytokines have any role in Wilson's disease? Clin Exp Immunol 2008;154:74-79.
32. Bruha R, Vitek L, Marecek Z, Pospisilova L, Nevsimalova S, Martasek P, et al. Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. J inherit Metab Dis 2012;35:541-548.
33. Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov 2014;13:433-444.
34. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002;99:7604-7609.
35. Pfeifer T, Buchebner M, Chandak PG, Patankar J, Kratzer A, Obrowsky S, et al. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol 2011;12:285-292.
36. Hoang MH, Jia Y, Jun HJ, Lee JH, Hwang KY, Choi DW, et al. Taurine is a liver X receptor-alpha ligand and activates transcription of key genes in the reverse cholesterol transport without inducing hepatic lipogenesis. Mol Nutr Food Res. 2012;56:900-911.
37. Gao M, Liu D. Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice. AAPS J 2013;15:744-752.
38. Lee JM, Gang GT, Kim DK, Kim YD, Koo SH, Lee CH, et al. Ursodeoxycholic acid inhibits liver X receptor alpha-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE. J Biol Chem 2014;289:1079-1091.
39. Jung UJ, Millman PN, Tall AR, Deckelbaum RJ. n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice. Biochim Biophys Acta 2011;1811:491-497.